STOCK TITAN

SilverCape proposes $3 cash buyout of PetMed Express (NASDAQ: PETS)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

SilverCape Investments Limited, a Cayman Islands investor, has filed an amended Schedule 13D stating it holds 2,579,696 shares of PetMed Express common stock, or about 12.07% of the company based on 21,365,782 shares outstanding as of May 22, 2026.

On June 29, 2026, SilverCape sent a revised non-binding proposal to PetMed Express’ CEO and board to take the company private by acquiring 100% of the outstanding common stock for $3.00 per share in cash. The proposal is subject to further due diligence and negotiation and would require a mutually acceptable definitive agreement, including board actions to neutralize the company’s shareholder rights plan or other antitakeover protections. The filing emphasizes there is no assurance a definitive agreement will be signed or that any transaction will be completed, and that SilverCape may change, withdraw, or further pursue its proposal at any time.

Positive

  • SilverCape’s revised non-binding proposal to acquire 100% of PetMed Express for $3.00 per share in cash signals concrete strategic interest in a potential going‑private transaction.

Negative

  • None.

Insights

SilverCape reveals a 12.07% stake and a $3.00-per-share, non-binding go-private proposal for PetMed Express.

SilverCape reports beneficial ownership of 2,579,696 PetMed Express shares, representing about 12.07% of outstanding common stock. This establishes it as a significant shareholder with meaningful influence over strategic discussions. Peter Kennedy, its managing director, has voting and investment power but disclaims personal beneficial ownership.

The filing discloses a revised, non-binding proposal to acquire 100% of the company for $3.00 per share in cash. The proposal is conditioned on further due diligence and a mutually acceptable definitive agreement, including actions by the board to render the shareholder rights plan and other antitakeover measures inapplicable. Until such a definitive agreement is executed, there is no binding obligation on any party.

SilverCape reserves broad flexibility: it may modify or withdraw the proposal, engage other shareholders, or buy or sell shares depending on factors like the company’s performance, stock price, and general market conditions. Future company communications or filings would clarify whether the board engages with SilverCape and whether any definitive agreement for a going‑private transaction is reached.

Beneficial ownership 2,579,696 shares SilverCape holdings as of Amendment No. 2 filing
Ownership percentage 12.07% of common stock Based on 21,365,782 shares outstanding as of May 22, 2026
Shares outstanding 21,365,782 shares PetMed Express common stock outstanding as of May 22, 2026
Proposed transaction price $3.00 per share Non-binding cash offer to acquire 100% of outstanding common stock
Schedule 13D amendment Amendment No. 2 Updates purpose of transaction and current holdings
Event date June 29, 2026 Date of event requiring the Schedule 13D/A filing
Schedule 13D regulatory
"If the filing person has previously filed a statement on Schedule 13G to report the acquisition..."
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
beneficially owned financial
"As of the filing date of this Amendment No. 2, SilverCape is the holder of record of 2,579,696 shares of Common Stock, representing approximately 12.07% of the shares of Common Stock."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
non-binding proposal financial
"providing a revised non-binding proposal (as revised, the "Proposal") to take the Issuer private..."
A non-binding proposal is an offer or plan presented by one party that outlines terms they would like to pursue but does not create a legally enforceable obligation. Think of it like a detailed handshake or a draft invitation to negotiate: it signals intent and frames possible outcomes, but either side can walk away or change terms without legal penalty. Investors watch these because they can move a stock’s price by suggesting a possible deal, yet they carry higher uncertainty than formal agreements.
Definitive Agreement regulatory
"subject in all respects to, among other things... the execution of a mutually acceptable definitive agreement..."
A definitive agreement is a formal, legally binding document that outlines the final terms and conditions of a deal or transaction, such as a sale or partnership. It acts like a detailed contract that confirms all parties have agreed on the key details, making the deal official. For investors, it signals that the agreement is settled and moving toward completion, providing clarity and security about the transaction.
shareholder rights plan regulatory
"including, without limitation, that the Issuer and its board of directors take all actions necessary to render inapplicable the Issuer's shareholder rights plan or other similar antitakeover protections..."
A shareholder rights plan is a board-approved defense that makes an unsolicited takeover harder by triggering measures—such as issuing extra shares or special rights—if one investor accumulates a large stake without board approval. Think of it as a temporary roadblock that protects existing management and gives the company time to seek better offers. It matters to investors because it can affect share price, takeover chances, and whether a competing buyer can quickly buy control.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





716382106

(CUSIP Number)
Michael Penney
Arnold & Porter Kaye Scholer LLP, 250 W. 55th Street
New York, NY, 10019
(212) 836-8000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
06/29/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
(1) The percent of class represented is based on 21,365,782 shares of Common Stock outstanding as of May 22, 2026, as last reported by the Issuer in its Annual Report on Form 10-K for the fiscal year ended March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
(1) Peter Kennedy, the managing director of SilverCape Investments Limited ("SilverCape"), has voting and investment power with respect to the Common Stock held by SilverCape. Mr. Kennedy disclaims any beneficial ownership of the Common Stock beneficially owned by SilverCape. (2) The percent of class represented is based on 21,365,782 shares of Common Stock outstanding as of May 22, 2026, as last reported by the Issuer in its Annual Report on Form 10-K for the fiscal year ended March 31, 2026.


SCHEDULE 13D


SilverCape Investments Limited
Signature:/s/ Peter Kennedy
Name/Title:Managing Director
Date:06/29/2026
Peter Kennedy
Signature:/s/ Peter Kennedy
Name/Title:Managing Director
Date:06/29/2026

FAQ

What stake does SilverCape hold in PetMed Express (PETS)?

SilverCape beneficially owns 2,579,696 shares of PetMed Express common stock, representing about 12.07% of the company. This percentage is based on 21,365,782 shares outstanding as of May 22, 2026, as reported in PetMed Express’ Form 10-K.

What did SilverCape propose in its latest Schedule 13D/A for PETS?

SilverCape submitted a revised non-binding proposal to take PetMed Express private. It proposes acquiring 100% of the outstanding common stock for $3.00 per share in cash, subject to due diligence and negotiation of a mutually acceptable definitive agreement.

Is SilverCape’s $3.00-per-share offer for PetMed Express binding?

No, the proposal is explicitly described as non-binding. It depends on further due diligence and execution of a definitive agreement. The filing states there is no assurance a definitive agreement will be executed or that any going‑private transaction will be consummated.

What conditions must be met for the PetMed Express go-private proposal?

The proposal requires completion of SilverCape’s further due diligence and a mutually acceptable definitive agreement. That agreement would include customary terms and actions by the board to render the shareholder rights plan and other antitakeover protections inapplicable to the proposed transaction.

Can SilverCape change or withdraw its proposal for PETS?

Yes. The filing states the reporting persons may modify or withdraw the proposal at any time. They also may accelerate or terminate discussions, change terms, or take additional steps to further the potential transaction or support their investment without prior notice.